2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Goldman Sachs Reiterates Sell Rating on 2Seventy Bio Inc. (TSVT)
November 12, 2024 12:52 PM ESTGoldman Sachs analyst Salveen Richter reiterated a Sell rating and $2.00 price target on 2Seventy Bio Inc. (NASDAQ: TSVT).
The analyst comments "TSVT reported 3Q US Abecma sales of $77mn (as reported by partner BMY) vs. GSe/Visible Alpha consensus of $70mn/$70mn, with Abecma profit-share of $11mn (vs. GSe/consesnus of $7mn/$11mn); GAAP EPS of ($0.19) was in line with consensus of ($0.19) (vs. GSe of ($0.34); Exhibit 1). While 3Q Abecma... More
